MAR Platform. Autoimmune research, designed for the European data layer.
A research infrastructure for designing, deploying and running clinical, observational and real-world evidence studies in autoimmune disease — built on top of the data layer that Maia Clinical and Maia generate, including the largest European molecular mimicry repository, with access to a consented participant base.
Most autoimmune research is built on cohorts that are too small.
Too small, too geographically narrow, too clinically homogeneous to detect the patterns that actually move treatment forward. Cross-disease patterns, longitudinal treatment-response signatures, comorbidity dynamics, molecular mimicry mechanisms — these need infrastructure that does not yet exist at scale in Europe. MAR is the answer to that, and to the regulatory environment Europe is heading toward.
From study design to deployment.
Study design
Protocol templates for clinical, observational and real-world evidence studies in autoimmune disease. Methodology validated with European researchers.
Participant access
Connection to a consented participant base from across the Maia ecosystem. Recruitment that respects patient autonomy, with explicit opt-in for each study.
Data infrastructure
OMOP and FHIR-aligned data structures. Cross-disease cohort assembly. Longitudinal follow-up native to the platform.
Molecular mimicry repository
Europe's largest repository of documented pathogen-autoantigen sequence similarities — queryable by condition, pathogen and specialty. The foundation for studying autoimmune triggering mechanisms at scale.
PROMs at scale
Patient-reported outcome measures collected through Maia integrate natively into MAR — the patient voice as a first-class data source, not an afterthought.
Cross-border collaboration
Built for multi-centre, multi-country European studies. Designed to make GDPR and EHDS compliance the default, not a separate workstream.
Designed for EHDS 2029.
The European Health Data Space comes into force in 2029. It will reshape how secondary use of clinical data works across Europe — and what kind of research is viable. MAR is built from the start to fit that framework, not to be retrofitted into it.
Built for European autoimmune research.
MAR is designed for the four researcher profiles who need both real longitudinal data and European-scale infrastructure to work with it.
Academic researchers
Principal investigators in rheumatology, gastroenterology, dermatology, neurology and internal medicine running observational or interventional studies in autoimmune disease.
Patient organisations
Partner associations conducting their own research priorities, with their communities and on their terms — using infrastructure they would not otherwise have access to.
Public health institutions
Spanish and European public health bodies needing structured evidence on autoimmune disease burden, treatment access, and care pathways.
Cross-disease consortia
Initiatives investigating shared mechanisms across autoimmune conditions — the kind of research that requires data infrastructure spanning specialties.
A roadmap aligned with EHDS.
Other Neural Omega products
Shape it with us.
MAR Platform is in architectural design phase. If you lead autoimmune research and want to help define what the platform should do, we want to hear from you. Pilot study partnerships open for 2027.
Discuss collaboration →